PSI Insights

High placebo response rates in Crohn’s disease and ulcerative colitis trials continue to challenge endpoint interpretability, power assumptions, and development timelines. Download PSI’s new white paper for a practical framework to reduce placebo susceptibility in IBD studies through patient selection, endpoint strategy, corticosteroid management, and operational controls.